Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAISE study of etavopivat in sickle cell disease
PACTR202202745054588Not yet recruiting
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Randomised, double-blind trial in sickle cell disease (SCD) comparing Etavopivat with Placebo (2 arms). Primary endpoints: Improvement in hemoglobin and Annualized vaso-occlusive crisis rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202202745054588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202202745054588.